Inspire Medical (INSP) officer reports 327-share tax withholding event

Rhea-AI Filing Summary

Inspire Medical Systems, Inc. executive John Rondoni, the Chief Product and Innovation Officer, reported a tax-related share disposition. On February 9, 2026, 327 shares of common stock were withheld by the company at $66.33 per share to cover taxes on a vested restricted stock unit award. After this withholding, Rondoni directly beneficially owned 13,470 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rondoni John

(Last) (First) (Middle)

C/O INSPIRE MEDICAL SYSTEMS, INC.

5500 WAYZATA BLVD., SUITE 1600

(Street)

GOLDEN VALLEY MN 55416

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		F		327(1)	D	$66.33	13,470	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock that were withheld by the Issuer to satisfy taxes incident to vesting of a restricted stock unit award.

Remarks:

Title: Chief Product and Innovation Officer.

	/s/ Bryan Phillips, Attorney-in-Fact for John Rondoni	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did INSP executive John Rondoni report?

John Rondoni reported a tax-related share disposition. On February 9, 2026, 327 shares of Inspire Medical Systems common stock were withheld by the company to satisfy taxes due on a vesting restricted stock unit award.

Was the INSP Form 4 transaction an open-market sale of shares?

No, the Form 4 transaction was not an open-market sale. The 327 Inspire Medical Systems shares were withheld by the issuer to cover tax obligations tied to a restricted stock unit vesting, classified as a tax-withholding disposition under transaction code F.

How many INSP shares were involved in John Rondoni’s tax withholding?

The filing shows that 327 shares of Inspire Medical Systems common stock were withheld. These shares were used to satisfy tax obligations arising from the vesting of a restricted stock unit award, rather than being sold in the open market.

How many Inspire Medical Systems shares does John Rondoni own after this Form 4?

After the reported tax-withholding disposition, John Rondoni directly beneficially owned 13,470 shares of Inspire Medical Systems common stock. This figure reflects his holdings immediately following the 327-share withholding for tax purposes on February 9, 2026.

What does transaction code F mean in the INSP Form 4 filing?

Transaction code F indicates payment of an exercise price or tax liability by delivering securities. In this case, Inspire Medical Systems withheld 327 shares from John Rondoni to satisfy taxes due on a vesting restricted stock unit award.

What is John Rondoni’s role at Inspire Medical Systems, Inc.?

According to the filing, John Rondoni is an officer of Inspire Medical Systems, Inc., serving as Chief Product and Innovation Officer. His relationship to the issuer is reported as an officer, and the Form 4 reflects his personal equity-based compensation activity.